Novartis gets EU and Canadian clearances for Alcon takeover
This article was originally published in Scrip
Executive Summary
Novartis has secured regulatory clearance in the EU and Canada for its proposed acquisition of Alcon, subject to the company selling off certain ophthalmological and consumer eyecare products that were raising competition concerns, clearing further obstacles in its bid to take full control of the US eyecare group.